3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Carcinoma, Hepatocellular
2
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Liver Neoplasms
1
Liver Abscess
1
Colorectal Neoplasms
1
Carcinoma
1
Breast Neoplasms
1
Adenoma
1
Interventions
Prednisone
103
enzalutamide
76
Docetaxel
73
Abiraterone Acetate
68
Leuprolide
47
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
45
abiraterone
39
apalutamide
29
Prednisolone
27
bicalutamide
26
Zoledronic Acid
24
darolutamide
23
radium Ra 223 dichloride
22
pembrolizumab
22
Goserelin
22
Triptorelin Pamoate
17
cabazitaxel
16
Androgen Antagonists
15
sipuleucel-T
13
Injections
13
luprolide acetate gel depot
12
Dexamethasone
12
olaparib
11
gallium 68 PSMA-11
10
Mitoxantrone
10
Cyclophosphamide
10
Pluvicto
9
Ipilimumab
9
Dutasteride
9
relugolix
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Prostatic Neoplasms
×
gadolinium ethoxybenzyl DTPA
×
Clear all
NCT04373564
2026-01-22
ODYSSEY
Guerbet
Phase 4
Recruiting
2,076 enrolled